Extended Follow-Up Confirm Efficacy of First-Line Pembrolizumab/Lenvatinib Combo in Advanced Non–Clear Cell RCC

Frontline pembrolizumab plus lenvatinib continues to show benefit vs historical controls in advanced non–clear cell renal cell carcinoma.

Related Keywords

,Martinh Voss ,International Metastatic Renal Cell Carcinoma Database Consortium ,Merck Co Inc ,Merck Sharp Dohme ,Cancers Symposium ,Genitourinary Medical Oncology Service ,Memorial Sloan Kettering Cancer Center ,Merck Sharp ,Rhas Y ,Non Clear Cell Rcc ,Renal Cell Carcinoma ,Pembrolizumab ,Keytruda ,Lenvatinib ,Lenvima ,Phase 2 Keynote B61 Trial ,Nct04704219 ,2024 Genitourinary Cancers Symposium ,D ,First Line Pembrolizumab Plus Lenvatinib ,